This study reports a dual-targeted extracellular vesicle platform derived from pro-inflammatory M1 macrophages and functionalized with hyaluronic acid (HA) and cyclic RGD peptide (cRGD), referred to as M1EV_HA/cRGD. The authors designed these vesicles to serve as molecular bridges that simultaneously engage innate immune effector cells and tumor cells. The stated clinical problem motivating the work is that advanced or recurrent breast cancer treatment is limited by therapeutic resistance and an immunosuppressive tumor microenvironment (TME).
The dual-targeted design aims to address two parallel challenges: (1) insufficient immune cell engagement with solid tumors and (2) a hostile, immune-suppressive TME that blunts antitumor responses. By combining pro-inflammatory vesicle cargo with surface ligands for both immune cells and tumor cells, the platform is intended to increase spatial proximity and functional activation of effector cells at tumor sites.
M1EV_HA/cRGD uses two complementary targeting moieties. Hyaluronic acid (HA) is incorporated to engage CD44 receptors, which the authors report are present on natural killer (NK) cells. The cyclic RGD peptide (cRGD) is used to bind integrins that are overexpressed on tumor cells or tumor vasculature. In this way, the vesicles are engineered to tether NK cells directly to tumor cells via HA–CD44 interaction on the immune cell side and cRGD–integrin binding on the tumor side.
The dual-targeting strategy is emphasized as producing a physical link between immune effector cells and cancer cells, thereby increasing the likelihood of immune synapse formation, local delivery of effector signals, and concentrated cytotoxic activity.
Beyond physical tethering, M1EV_HA/cRGD carry the bioactive contents characteristic of M1 macrophage extracellular vesicles, including inflammatory cytokines and microRNAs. The authors describe these vesicle-borne factors as capable of reprogramming the immunosuppressive TME into a more pro-inflammatory environment. This reprogramming is intended to amplify immune activation within the tumor, rendering the microenvironment less permissive for tumor growth and resistance mechanisms.
The combined action—delivery of pro-inflammatory mediators plus directed immune–tumor engagement—is positioned as central to the reported enhancement of antitumor immunity.
The abstract reports that in vitro studies demonstrate M1EV_HA/cRGD markedly increase NK cell clustering at tumor cell sites, elevate NK activation status, and enhance NK-mediated cytotoxicity against breast cancer cells. These findings are presented as evidence that the dual-targeting vesicles both recruit and potentiate NK cell effector functions in controlled laboratory assays.
Specific experimental protocols, quantitative outcomes, or statistical measures are not detailed in the abstract; those methodological and numerical details were not reported in the source abstract and would require consulting the full article for complete information.
According to the article abstract, in vivo studies corroborate the in vitro results: M1EV_HA/cRGD enhance NK cell clustering at tumor sites and increase NK activation and tumor cell killing in animal models. The authors claim the dual-targeted vesicles can physically tether NK cells to tumors in vivo while delivering inflammatory cargo that reprograms the TME, amplifying antitumor immune responses.
Again, the abstract summarizes these outcomes but does not provide detailed experimental conditions, model descriptions, or quantitative results; such specifics are not reported in the provided source text.
The authors contrast the dual-targeting mechanism with single-targeted approaches, arguing that M1EV_HA/cRGD uniquely couples TME reprogramming with enhanced immune–tumor engagement. They present this integrated effect as a potential paradigm shift for solid tumor immunotherapy—particularly for breast cancer—by directly addressing mechanisms of treatment failure, overcoming therapeutic resistance, and improving survival outcomes.
The study frames M1EV_HA/cRGD as a platform that could be combined with NK cell–based therapies to increase efficacy against tumors that are otherwise refractory due to an immunosuppressive microenvironment.
This research is reported by Su Jin Kang and colleagues from the Department and Division of Bioengineering and associated centers at Incheon National University, South Korea. The work appears in Journal of Extracellular Vesicles (J Extracell Vesicles), October 2026; volume 15, issue 10, article e70379. PubMed identifier (PMID) 42814771 and DOI 10.1002/jev2.70379 are provided in the source. The abstract and metadata indicate both in vitro and in vivo evidence supporting the concept, but the abstract does not include detailed methods, numerical results, or safety and translational readiness data; those elements would require review of the full manuscript.